Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VOLITIONRX LTD Director's Dealing 2022

Apr 8, 2022

34395_dirs_2022-04-08_505011eb-a0ab-471a-8a29-fa3b7f597d96.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-04-07-05:00

Reporting Person: Futcher Edward (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-04-07-05:00 Common Stock A 1640 Acquired 39890 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-04-07-05:00 Stock Option (Right to Buy) $3.40 A 3022 Acquired 2031-08-03-05:00 Common Stock (3022) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 356000 Indirect

Footnotes

F1: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

F2: These shares of Common Stock are beneficially owned by The Dill Faulkes Educational Trust Limited ("DFET"), a UK registered charity. Dr. Futcher serves as a director and trustee of DFET and shares voting and dispositive control over these shares but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

F3: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively.